Significance of cyclin Dl overexpression and amplification in ductal hyperplasia, carcinoma in situ and invasive carcinoma in Egyptian female breast

International Journal of Cancer Research

Volumn 6, Issue 4, 2010, Pages 202-219

  Abd El Maqsoud, N M R ^a   Aly, Moatasem M ^a  

^a Minia University   (Egypt)

Author keywords

Cyclin Dl; Ductal carcinoma in situ; Ductal hyperplasia; Fluorescence in situ hybridization; Immunohistochemistry; Invasive breast carcinoma

Indexed keywords

CYCLIN D1; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST HYPERPLASIA; CANCER STAGING; CONTROLLED STUDY; EGYPT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC CORRELATION; HISTOLOGY; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN EXPRESSION;

EID: 78149451083     PISSN: 18119727     EISSN: 18119735     Source Type: Journal    
DOI: 10.3923/ijcr.2010.202.219     Document Type: Article

References (62)

1. Ahnstrom, M., B. Nordenskjold, L.E. Rutqvist, L. Skoog and O. Stal, 2005. Role of cyclin Dl in ErbB2-positive breast cancer and tamoxifen resistance. Breast Cancer Res. Treat, 91: 145-151.
2. Al-Kuraya, K., P. Schraml, J. Torhorst, C. Tapia and B. Zaharieva et al, 2004. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res., 64: 8534-8540.
3. Alle, K.M., S.M. Henshall, A.S. Field and R.L. Sutherland, 1998. Cyclin Dl protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clin Cancer Res., 4: 847-854.
4. Arnold, A. and A. Papanikolaou, 2005. Cyclin Dl in breast cancer pathogenesis. J. Clin. Oncol, 23: 4215-4224.
5. Baldin, V., J. Lukas, M.J. Marcote, M. Pagano and G. Draetta, 1993. Cyclin Dl is a nuclear protein required for cell cycle progression in Gl. Genes Dev., 7: 812-821.
6. Barnes,D.M., 1997. CyclinDl in mammary carcinoma. J. Pathol., 181: 267-269.
7. Bieche, I, M. Olivi, C. Nogues, M. VidaudandR. Lidereau, 2002. Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. Br. J. Cancer, 86: 580-586.
8. Bilalovic, N., S. Vranic, H. Basic, A. Tatarevic and I. Selak, 2005. Immunohistochemical evaluation of cyclinDl in breast cancer. Croat Med. J., 46: 382-388.
9. Brown, L.A., J. Irving, R. Parker, H. Kim and J.Z. Press et al, 2006. Amplification of EMSY, a novel oncogene on llql3, in high grade ovarian surface epithelial carcinomas Gynecol. Oncol, 100: 264-270.
10. Butt, A.J., CM. McNeil, E.A. Musgrove and R.L. Sutherland, 2005. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: The potential roles of c-Myc, cyclinDl and cyclinE. Endocr Relat Cancer, 12: S47-S59.
11. Carter, C.L., C. Allen and D.E. Henson, 1989. Relation of tumor size, lymph node status and survival in 24, 740 breast cancer cases. Cancer, 63: 181-187.
12. Cheuk, W., K.O. Wong, C.S. Wong and J.K. Chan, 2004. Consistent immunostaining for cyclin Dl can be achieved on a routine basis using a newly available rabbit monoclonal antibody. Am. J. Surg. Pathol, 28: 801-807.
13. Cho, E.Y., Y.L. Choi, J. J. Han, K.M. Kim and Y.L. Oh, 2008. Expression and amplification of Her2, EGFR and cyclinDl in breast cancer: Immunohistochemistry and chromogenic in situ hybridization. Pathol. Int., 58: 17-25.
14. Cuny, M., A. Kramar, F. Courjal, V. Johannsdottir and B. Iacopetta et al, 2000. Relating genotype and phenotype in breast cancer: An analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res., 60: 1077-1083.
15. El-Bolkainy, M.N., M.A. Nouh and T.K. El-Bolkainy, 2005. Topgraphic Pathology of Cancer. 3rdEdn., Chap. 7. Cairo University, Egypt, pp: 57-64.
16. Ellis, I.O., M. Galea, N. Broughton, A. Locker and R.W. Blarney et al., 1992. Pathological prognostic factors in breast cancer: II. Histological type: Relationship with survival in a large study with long term follow up. Histopathology, 20: 479-489.
17. Elsheikh, S., A.R. Green, M.A. Aleskandarany, M. Grainge and C.E. Paish et al, 2008. CCNDl amplification and cyclin Dl expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Res. Treat, 109: 325-335.
18. Elston, C.W. and I.O. Ellis, 1991. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology, 19: 403-410.
19. Esteva, F. J. and G.N. Hortobagyi, 2004. Prognostic molecular markers in early breast cancer. Breast Cancer Res., 6: 109-118.
20. Fiche, M., H. Avet-Loiseau, CM. Maugard, C. Sagan and M.F. Heymann et al, 2000. Gene amplifications detected by fluorescence in situ hybridization in pure intraductal breas carcinomas: Relation to morphology, cell proliferation and expression of breast cancer-related genes. Int. J. Cancer, 89: 403-410.
21. Fitzgibbons, P.L., D.L. Page, D. Weaver, A.D. Thor and D.C. Allred et al, 2000. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch. Pathol. Lab. Med., 124: 966-978.
22. Fu, M., C. Wang, Z. Li, T. Sakamaki and R.G. Pestell, 2004. Mimreview: CyclmDl: Normal and abnormal functions. Endocrinology, 145: 5439-5447.
23. Gillett, C, V. Fantl and R. Smith, 1994. Amplification and overexpression of cyclin Dl in reast cancer detected by immunohistochemical staining. Cancer Res., 54: 1812-1817.
24. Gillett C.E., A.H. Lee, R.R. Millis and D.M. Barnes, 1998. Cyclin Dl and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia. J. Pathol., 184: 396-400.
25. Harvey, J.M., G.M. Clark, C.K. Osborne and D.C. Allred, 1999. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol., 17: 1474-1481.
26. Heffelfinger, S.C.,R. Yassin,M.A. Miller and E.E. Lower, 2000. CyclmDl,retinoblastoma, p53 and Her2/neu protein expression in preinvasive breast pathologies: Correlation with vascularity. Pathobiology, 68: 129-136.
27. Hermanek, P. and L.H. Sobin, 1992. TNM Classification of International Union Against Cancer: TNM Atlas. 4th Edn., 3rd Revision, Springer-Verlag, Berlin.
28. Holland, R., J.L. Peterse, R.R. Millis, V. Eusebi and D. Faverly etal., 1994. Ductal carcinoma in situ: A proposal for a new classification. Semin Diagn. Pathol., 11: 167-180.
29. Hwang, T.S., H.S. Han, Y.C. Hong, HJ. Lee and N.S. Paik, 2003. Prognostic value of combined analysis of cyclin Dl and estrogen receptor status in breast cancer patients. Pathol. Int., 53: 74-80.
30. Jirstrom, K., M. Stendahl and L. Ryden, 2005. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin Dl gene amplification. Cancer Res., 65: 8009-8016.
31. Lebeau, A., D. Deimling, C. Kaltz, A. Sendelhofert and A. Iff et al, 2001. Her-2/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization. J. Clin. Oncol., 19: 354-363.
32. Lebeau, A., A. Unholzer, G. Amann, M. Kronawitter and I. Bauerfeind et al., 2003. EGFR, HER-2/neu, cyclin Dl, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast. Breast Cancer Res. Treat, 79: 187-198.
33. Lee, A., W.C. Park, H.W. Yim, M.A. Lee and G. Park et al, 2007. Expression of c-erbB2, cyclin Dl and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast. Jap. J. Clin. Oncol, 37: 708-714.
34. Loden, M., M. Stighall,N.H. Nielsen, G. Roos and S.O. Emdin et al, 2002. The cyclinDl high and cyclin E high subgroups of breast cancer: Separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node. Oncogene, 21: 4680-4690.
35. Luo, M.L., X.M. Shen, Y. Zhang, F. Wei and X. Xu et al, 2006. Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. Cancer Res., 66: 11690-11699.
36. Molland, J.G., M. Donnellan, N.C. Janu, H.L. Carmalt and C.W, Kennedy et al, 2004. Infiltrating lobular carcinoma: A comparison of diagnosis, management and outcome with infiltrating duct carcinoma. Breast, 13: 389-396.
37. Mommers, E.C.M, P.J. van Diest, A.M. Leonhart, C.J.L.M. Meyer and J.P.A. Baak, 1998. Expression of proliferation and apoptos is-related proteins in usual ductalhyperplasia of the breast. Human Pathol., 29: 1539-1545.
38. Mrhalova, M., R. Kodet and P. Strnad, 2002. Invasive ductal carcinoma of the breast: Study of the number of copies of the CCND1 gene and chromosome 11 using fluorescence in situ hybridization (FISH) in comparison with expression of cyclin Dl protein and estrogen receptors (ER alpha) with immunohistochemical detection. Cas Lek Cesk, 141: 708-714.
39. Naidu, R, N.A. Wahab, M.M. Yadav and M.K. Kutty, 2002. Expression and amplification of cyclin Dl in primary breast carcinomas: Relationship with histopathological types and clinico-pathological parameters. Oncol. Rep., 9: 409-416.
40. Neuman, E., M.H. Ladha, N. Lin, T.M. Upton and S. J. Miller et al., 1997. Cyclin Dl stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol. Cell. Biol., 17: 5338-5347.
41. Nishimura, R, T. Saeki, S. Ohsumi, Y. Tani and S. Takashima, 2007. Immunohistochemical expression of hormone receptors and the histological characteristics of biochemically hormone receptor negative breast cancers. Breast Cancer, 14: 100-104.
42. Oh, Y.L., J.S. Choi, S.Y. Song, Y.H. Ko and B.K. Banetal, 2001. Expression of p21Wafl, p27Kipl and cyclin Dl proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status. Pathol. Int.,51: 94-99.
43. Ormandy, C.J., E.A. Musgrove, R. Hui, R.J. Daly and R.L. Sutherland, 2003. Cyclin Dl, EMS1 and 11 ql 3 amplification in breast cancer. Breast Cancer Res. Treat, 78: 323-333.
44. Page, D.L. and L.W. Rogers, 1992. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Human Pathol., 23: 1095-1097.
45. Parkin, D.M., S.L. Whelan, J. Ferlay, L. Teppo and D.B. Thomas, 2002. Cancer Incidence in Five Continents. Vol. 8. IARC Scientific Publications No. 155. International Agency for Research on Cancer, Lyon, France, ISBN-13: 9789283221555, pp: 838.
46. Planas-Silva, M.D. and R.A. Weinberg, 1997. Estrogen dependent cyclin E-cdk2 activation through p21 redistribution Mol CellBiol, 17: 4059-4069.
47. Recht, A., S.B. Edge, L.J. Solin, D.S. Robinson and A. Estabrooke et al., 2001. Postmastectomy radiotherapy: Clinical practice guidelines of the American Society of Clinical Oncology. J. Clm. Oncol., 19: 1539-1569.
48. Reis-Filho, J.S., K. Savage, M.B. Lambros, M. James and D. Steele et al., 2006. Cyclin Dl protein overexpression and CCND1 amplification in breast carcinomas: An immunohistochemical and chromogenic in situ hybridisation analysis. Mod. Pathol., 19: 999-1009.
49. Shibata, T., S. Uryu, A. Kokubu, F. Hosoda and M. Ohki et al, 2005. Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: Its association with clinicopathologic features. Clin. Cancer Res., 11: 6177-6185.
50. Shoker, B.S., C. Jarvis, R.B. Clarke, E. Anderson and C. Munro et al., 2000. Abnormal regulation of oestrogen receptor in benign breast lesions. J. Clin. Pathol., 53: 778-783.
51. Shoker, B.S., C. Jarvis, M.P.A. Davies, M. Iqbal and D.R. Sibson et al, 2001. Sloane JP. Immunodetectable cyclin Dl is associated with oestrogen receptor but not Ki67 in normal, cancerous andprecancerous breast lesions. Br. J. Cancer, 84: 1064-1069.
52. Simpson, J.F., D.E. Quan, F. O'Malley, T. Odom-MaryonandP.E. Clarke, 1997. Amplification of CCND1 and expression of its protein product, cyclin Dl, in ductal carcinoma in situ of the breast. Am. J. Pathol, 151: 161-168.
53. Soslow, R.A.,D.L. Carlson, M.G. Horenstein and M.P. Osborne, 2000. A comparison of cell cycle markers in well differentiated lobular and ductal carcinomas. Breast Cancer Res. Treat, 61: 161-170.
54. Stendahl, M., A. Kronblad, L. Ryden, S. Emdin, N.O. Bengtsson and G. Landberg, 2004. Cyclin Dloverexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br. J. Cancer, 90: 1942-1948.
55. Sutherland, R.L. and E.A. Musgrove, 2004. Cyclins and breast cancer. J. Mammary Gland Biol. Neoplasm, 9: 95-104.
56. Sutherland, R.L., J.A. Hamilton, K.J.E. Sweeney, C.K.W. Watts and E.A. Musgrove, 1995. Expression and regulation of cyclin genes in breast cancer. Acta Oncol., 34: 651-656.
57. Umekita, Y. and H. Yoshida, 2000. Cyclin Dl expression in ductal carcinoma in situ, atypical ductal hyperplasia and usual ductal hyperplasia: An immunohistochemical study. Pathol. Int., 50: 527-530.
58. VanDiest, P.J., R.J. Michalides, L. Jannink, P. van der Valk and H.L. Peterse et al, 1997. Cyclin Dl expression in invasive breast cancer. Correlations and prognostic value. Am. J. Pathol., 150: 705-711.
59. Vos, C.B., N.T. Ter Haar, J.L. Peterse, C. J. Cornelisse and M J. van de Vyver, 1999. Cyclin Dl gene amplification and overexpression are present in ductal carcinoma in situ of the breast. J. Pathol, 187: 279-284.
60. Worsley, S.D., B.A. Jennings, K.H. Khalil, M. Mole and A.C. Girling, 1996. Cyclin Dl amplification and expression in human breast carcinoma: Correlation with histological prognostic markers and oestrogen receptor expression. Clin. Mol. Pathol., 49: M46-M50.
61. Zaharieva, B.M., R. Simon, P.A. Diener, D. Ackermann and R. Maurer et al, 2003. High-throughput tissue microarray analysis of 11 ql 3 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer. J. Pathol., 201: 603-608.
62. Zukerberg, L.R., W.I. Yang, M. Gadd, A.D. Thor and F.C. Koerner et al., 1995. Cyclin Dl (PRAD1) protein expression in breast cancer: Approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin Dl oncogene. Mod. Pathol., 8: 560-567.